VHPKQHR peptide modified magnetic mesoporous nanoparticles for MRI detection of atherosclerosis lesions

References

• Herrington W, Lacey B, Sherliker P, et al. Epidemiology of atherosclerosis and the potential to reduce the global burden of atherothrombotic disease. Circ Res. 2016;118:535–546.
   PubMed Web of Science ®Google Scholar
• Fausto N. Atherosclerosis in young people: the value of the autopsy for studies of the epidemiology and pathobiology of disease. Am J Pathol. 1998;154:1021–1022.
   Web of Science ®Google Scholar
• Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2013;368:2004–2013.
   PubMed Web of Science ®Google Scholar
• Kramer CM, Anderson JD. MRI of atherosclerosis: diagnosis and monitoring therapy. Exp Rev Cardiovasc Ther. 2007;5:69–80.
   PubMedGoogle Scholar
• Raggi P, Baldassarre D, Day S, et al. Non-invasive imaging of atherosclerosis regression with magnetic resonance to guide drug development. Atherosclerosis. 2016;251:476–482.
   PubMed Web of Science ®Google Scholar
• Estelrich J, Sanchez-Martin MJ, Busquets MA. Nanoparticles in magnetic resonance imaging: from simple to dual contrast agents. Int J Nanomedicine. 2015;10:1727–1741.
   PubMed Web of Science ®Google Scholar
• Jin K, Luo Z, Zhang B, et al. Biomimetic nanoparticles for inflammation targeting. Acta Pharm Sin B. 2018;8:23–33.
   PubMed Web of Science ®Google Scholar
• Nakashima Y, Raines EW, Plump AS, et al. Upregulation of VCAM-1 and ICAM-1 at atherosclerosis-prone sites on the endothelium in the ApoE-deficient mouse. Arterioscler Thromb Vasc Biol. 1998;18:842–851.
   PubMed Web of Science ®Google Scholar
• Trpkovic A, Resanovic I, Stanimirovic J, et al. Oxidized low-density lipoprotein as a biomarker of cardiovascular diseases. Crit Rev Clin Lab Sci. 2015;52:70–85.
   PubMed Web of Science ®Google Scholar
• Seimon T, Tabas I. Mechanisms and consequences of macrophage apoptosis in atherosclerosis. J Lipid Res. 2009;50 (Suppl):S382–S387.
   PubMed Web of Science ®Google Scholar
• Manduteanu I, Simionescu M. Inflammation in atherosclerosis: a cause or a result of vascular disorders? J Cell Mol Med. 2012;16:1978–1990.
   PubMed Web of Science ®Google Scholar
• Nahrendorf M, Keliher E, Panizzi P, et al. 18F-4V for PET-CT imaging of VCAM-1 expression in atherosclerosis. JACC Cardiovasc Imaging. 2009;2:1213–1222.
   PubMed Web of Science ®Google Scholar
• Serres S, Mardiguian S, Campbell SJ, et al. VCAM-1-targeted magnetic resonance imaging reveals subclinical disease in a mouse model of multiple sclerosis. FASEB J. 2011;25:4415–4422.
   PubMed Web of Science ®Google Scholar
• Zhang X, Liu C, Hu F, et al. PET imaging of VCAM-1 expression and monitoring therapy response in tumor with a (68)Ga-labeled single chain variable fragment. Mol Pharm. 2018;15:609–618.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhao Q, Han N, et al. Mesoporous silica nanoparticles in drug delivery and biomedical applications. Nanomedicine. 2015;11:313–327.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xu J. Mesoporous silica nanoparticle-based intelligent drug delivery system for bienzyme-responsive tumour targeting and controlled release. R Soc Open Sci. 2018;5:1–10.
   Web of Science ®Google Scholar
• Wei Y, Gao L, Wang L, et al. Polydopamine and peptide decorated doxorubicin-loaded mesoporous silica nanoparticles as a targeted drug delivery system for bladder cancer therapy. Drug Deliv. 2017;24:681–691.
   PubMed Web of Science ®Google Scholar
• Nahrendorf M, Jaffer FA, Kelly KA, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation. 2006;114:1504–1511.
   PubMed Web of Science ®Google Scholar
• Kelly KA, Nahrendorf M, Yu AM, et al. In vivo phage display selection yields atherosclerotic plaque targeted peptides for imaging. Mol Imaging Biol. 2006;8:201–207.
   PubMed Web of Science ®Google Scholar
• Swaminathan S. Gadolinium toxicity: iron and ferroportin as central targets. Magn Reson Imaging. 2016;34:1373–1376.
   PubMed Web of Science ®Google Scholar
• Henderson L, Neumann O, Kaffes C, et al. Routes to potentially safer T1 magnetic resonance imaging contrast in a compact plasmonic nanoparticle with enhanced fluorescence. ACS Nano. 2018;12:8214–8223.
   PubMed Web of Science ®Google Scholar
• Shi Q, Wang J, Wang XL, et al. Comparative analysis of vascular endothelial cell activation by TNF-alpha and LPS in humans and baboons. Cell Biochem Biophys. 2004;40:289–303.
   PubMed Web of Science ®Google Scholar
• Quillard T, Libby P. Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circ Res. 2012;111:231–244.
   PubMed Web of Science ®Google Scholar
• Khodabandehlou K, Masehi-Lano JJ, Poon C, et al. Targeting cell adhesion molecules with nanoparticles using in vivo and flow-based in vitro models of atherosclerosis. Exp Biol Med (Maywood). 2017;242:799–812.
   PubMed Web of Science ®Google Scholar
• Smith BA, Smith BD. Biomarkers and molecular probes for cell death imaging and targeted therapeutics. Bioconjugate Chem. 2012;23:1989–2006.
   PubMed Web of Science ®Google Scholar
• Jeong WJ, Bu J, Kubiatowicz LJ, et al. Peptide-nanoparticle conjugates: a next generation of diagnostic and therapeutic platforms? Nano Converg. 2018;5:38.
   PubMed Web of Science ®Google Scholar
• Mlinar LB, Chung EJ, Wonder EA, et al. Active targeting of early and mid-stage atherosclerotic plaques using self-assembled peptide amphiphile micelles. Biomaterials. 2014;35:8678–8686.
   PubMed Web of Science ®Google Scholar
• Su T, Wang YB, Han D, et al. Multimodality imaging of angiogenesis in a rabbit atherosclerotic model by GEBP11 peptide targeted nanoparticles. Theranostics. 2017;7:4791–4804.
   PubMed Web of Science ®Google Scholar
• Cloft HJ, Lynn MJ, Feldmann E, et al. Risk of cerebral angiography in patients with symptomatic intracranial atherosclerotic stenosis. Cerebrovasc Dis. 2011;31:588–591.
   PubMed Web of Science ®Google Scholar
• Willinsky RA, Taylor SM, terBrugge K, et al. Neuroradiology neurologic complications of cerebral angiography prospective analysis of 2,899 procedures and review of the literature. Radiology. 2003;227:522–528.
   PubMed Web of Science ®Google Scholar
• Achenbach S, Raggi P. Imaging of coronary atherosclerosis by computed tomography. Eur Heart J. 2010;31:1442–1448.
   PubMed Web of Science ®Google Scholar
• Moghbel M, Al-Zaghal A, Werner TJ, et al. The role of PET in evaluating atherosclerosis: a critical review. Semin Nucl Med. 2018;48:488–497.
   PubMed Web of Science ®Google Scholar
• Vithanarachchi S, Allen M. Strategies for target-specific contrast agents for magnetic resonance imaging. Cmi. 2012;1:12–25.
   Google Scholar
• Clappers N, Brouwer MA, Verheugt FW. Antiplatelet treatment for coronary heart disease. Heart. 2007;93:258–265.
   PubMed Web of Science ®Google Scholar
• Libby MAP. Lipid lowering therapy in atherosclerosis. Semin Vasc Med. 2004;4:257–367.
   Google Scholar
• Din FU, Aman W, Ullah I, et al. Effective use of nanocarriers as drug delivery systems for the treatment of selected tumors. Ijn. 2017;12:7291–7309.
   Web of Science ®Google Scholar
• Araujo LA, Addor F, Campos PM. Use of silicon for skin and hair care: an approach of chemical forms available and efficacy. An Bras Dermatol. 2016;91:331–335.
   PubMed Web of Science ®Google Scholar
• Robberecht H, Van Dyck K, Bosscher D, et al. Silicon in foods: content and bioavailability. Int J Food Prop. 2008;11:638–645.
   Web of Science ®Google Scholar